The FDA laid out eight observations it determined needed correction at the facility.
The FDA this week made public a Form 483 it sent to Zimmer Biomet (NYSE:ZBH) over issues it found during an inspection of its Warsaw, Ind.-based plant last year, laying out eight observations it determined need correction at the facility.
The federal watchdog released a 12-page document covering the issues it found during the inspection, which took place between Oct. 2, 2017 and Oct. 16, 2017, a number of which were repeat issues that the agency had previously noted during prior inspections.
The full list of observations made in the Form 483 include:
